Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2007, vol. 16, nr 3, May-June, p. 347–352

Publication type: editorial article

Language: English

Cyclooxygenase II – A Role in Gastric Cancer Treatment

Rola cyklooksygenazy w leczeniu raka żołądka

Kenji Ogawa1,, Kazuhiko Yoshimatsu1,

1 Department of Surgery, Tokyo Women’s Medical University Medical Center East, Japan


Recent studies have demonstrated that increased amount of prostaglandin E2 (PGE2) produced by overexpression of cyclooxygenase−2 (COX−2)/microsomal PGE synthase−1 (mPGES−1) is involved in tumor proliferation. Furthermore, relationships with epidermal growth factor (EGF)/mitogen activated protein (MAP) kinase signal pathway related to cell proliferation and Akt/protein kinase B (PKB) related to resistance of apoptosis are being clarified. Association of COX−2 with gastric cancer has not been established as clearly as in colon cancer. However, increased expression of COX−2 in gastric cancer was confirmed, and in cell culture or animal models, influence of COX−2 on tumor proliferation was indicated. Thus, the usefulness of COX−2 inhibitor in treatment has been demonstrated. However, in precancerous lesions of gastric cancer, COX−2 expression is controversial and the usefulness of COX−2 inhibitor has not been demonstrated. Further studies about COX−2 and gastric cancer including clinical trials are needed, and also more studies should be performed about other PGE2 related enzymes as well as COX−2.

Key words

cyclooxygenase−2 (COX−2), microsomal prostaglandin E synthase−1 (mPGES−1), gastric cancer, chemoprevention, COX−2 inhibitor

References (56)

  1. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr.: Aspirin use and risk of fatal cancer. Cancer Res 1993, 53, 1322–1327.
  2. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ: Effect of anti−inflammatory drugs on overall risk of common cancer: case−control study in general practice research database. BMJ 2000, 320, 1642–1646.
  3. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, Subbaramaiah K Cyclo−oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001, 2, 544–551.
  4. Rigas B, Goldman IS, Levine L: Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993, 122, 518–522.
  5. Tanioka T, Nakatani Y, Semmyo N, Murakami M, Kudo I: Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase−1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 2000, 275, 32775–32782.
  6. Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F, Ikeda T, Fueki M, Ueno A, Oh S, Kudo I: Regulation of prostaglandin E2 biosynthesis by inducible membrane−associated prostaglandin E2 synthase that acts in concert with cyclooxygenase−2. J Biol Chem 2000, 275, 32783–32792.
  7. Yoshimatsu K, Golijanin D, Paty PB, Soslow RA, Jakobsson PJ, DeLellis RA, Subbaramaiah K, Dannenberg AJ: Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res 2001, 7, 3971–3976.
  8. Yoshimatsu K, Altorki NK, Golijanin D, Zhang F, Jakobsson PJ, Dannenberg AJ, Subbaramaiah K: Inducible prostaglandin E synthase is overexpressed in non−small cell lung cancer. Clin Cancer Res 2001, 7, 2669–2674.
  9. Cohen EG, Almahmeed T, Du B, Golijanin D, Boyle JO, Soslow RA, Subbaramaiah K., Dannenberg, AJ: Microsomal prostaglandin E synthase−1 is overexpressed in head and neck squamous cell carcinoma. Clin Cancer Res 2003, 9, 3425–3430.
  10. Jang TJ: Expression of proteins related to prostaglandin E2 biosynthesis is increased in human gastric cancer and during gastric carcinogenesis. Virchows. Arch. 2004, 445, 564–571.
  11. Mehrotra S, Morimiya A, Agarwal B, Konger R, Badve S: Microsomal prostaglandin E (2) synthase−1 in breast cancer: a potential target for therapy. J Pathol 2006, 208, 356–363.
  12. Golijanin D, Tan JY, Kazior A, Cohen EG, Russo P, Dalbagni G, Auborn KJ, Subbaramaiah K, Dannenberg AJ: Cyclooxygenase−2 and microsomal prostaglandin E synthase−1 are overexpressed in squamous cell carcinoma of the penis. Clin. Cance.r Res. 2004, 10, 1024–1031.
  13. Jang TJ, Min SK, Bae JD, Jung KH, Lee JI, Kim JR, Ahn WS: Expression of cyclooxygenase 2, microsomal prostaglandin E synthase 1, and EP receptors is increased in rat oesophageal squamous cell dysplasia and Barrett’s metaplasia induced by duodenal contents reflux. Gut 2004, 53, 27–33.
  14. Van Rees BP, Sivula A, Thoren S, Yokozaki H, Jakobsson PJ, Offerhaus GJA, Ristimaki A: Expression of microsomal prostaglandin E synthase−1 in intestinal type gastric adenocarcinoma and in gastric cancer cell lines. Int J Cancer 2003, 107, 551–556.
  15. Mehrotra S, Morimiya A, Agarwal B, Konger R, Badve S: Microsomal prostaglandin E2 synthase−1 in breast cancer: a potential target for therapy J Pathol 2006, 208, 356–363.
  16. Martey CA, Baglole CJ, Gasiewicz TA, Sime PJ, Phipps RP: The aryl hydrocarbon receptor is a regulator of cigarette smoke induction of the cyclooxygenase and prostaglandin pathways in human lung fibroblasts Am J Physiol Lung Cell Mol Physiol 2005, 289, L391–L399.
  17. Shi Y, Cui L, Dai G, Chen J, Pan H, Song L, Cheng S, Wang X: Elevated prostaglandin E2 level via cPLA2− COX−2−mPGES−1 pathway involved in bladder carcinogenesis induced by terephthalic acid−calculi in Wistar rat. Prostaglandins Leukot Essent Fatty Acids 2006, 74, 309–315.
  18. Rask K, Zhu Y, Wang W, Hedin L, Sundfeldt K: Ovarian epithelial cancer: a role for PGE2−synthesis and signalling in malignant transformation and progression. Mol Cancer 2006, 5, 62.
  19. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN: Host cyclooxygenase−2 modulates carcinoma growth. J Clin Invest 2000, 105, 1589–1594.
  20. Seno H, Oshima M, Ishikawa TO, Oshima H, Takaku K, Chiba T, Narumiya S, Taketo MM: Cyclooxygenase 2− and prostaglandin E(2) receptor EP(2)−dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res 2002, 62, 506–511.
  21. Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S, Oshima M, Taketo MM: Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 2001, 7, 1048–1051.
  22. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS: Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002, 8, 289–293.
  23. Kamei D, Murakami M, Nakatani Y, Ishikawa Y, Ishii T, Kudo I: Potential role of microsomal prostaglandin E synthase−1 in tumorigenesis. J Biol Chem 2003, 278, 19396–19405.
  24. Oshima H, Oshima M, Inaba K, Taketo MM: Hyperplastic gastric tumors induced by activated macrophages in COX−2/mPGES−1 transgenic mice. EMBO J 2004, 23, 1669–1678.
  25. Oshima H, Matsunaga A, Fujimura T, Tsukamoto T, Taketo MM, Oshima M: Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway. Gastroenterology. 2006, 131, 1086–1095.
  26. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr.: Aspirin use and risk of fatal cancer. Cancer Res 1993, 53, 1322–1327.
  27. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ: Effect of anti−inflammatory drugs on overall risk of common cancer: case−control study in general practice research database. BMJ. 2000, 320, 1642–1646.
  28. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M: Expression of cyclooxygenase−2 in human gastric carcinoma. Cancer Res 1997, 57, 1276–1280.
  29. Yamagata R, Shimoyama T, Fukuda S, Yoshimura T, Tanaka M, Munakata A: Cyclooxygenase−2 expression is increased in early intestinal−type gastric cancer and gastric mucosa with intestinal metaplasia. Eur J Gastroenterol Hepatol 2002, 14, 359–363.
  30. Li HX, Chang XM, Song ZJ, He SX: Correlation between expression of cyclooxygenase−2 and angiogenesis in human gastric adenocarcinoma. World J Gastroenterol 2003, 9, 674–677.
  31. Sung JJ, Leung WK, Go MY, To KF, Cheng AS, Ng EK, Chan FK: Cyclooxygenase−2 expression in Helicobacter pylori−associated premalignant and malignant gastric lesions. Am J Pathol 2000, 157, 729–735.
  32. Van Rees BP, Saukkonen K, Ristimaki A, Polkowski W, Tytgat GN, Drillenburg P, Offerhaus GJ: Cyclooxygenase−2 expression during carcinogenesis in the human stomach. J Pathol 2002, 196, 171–179.
  33. Tatsuguchi A, Sakamoto C: COX−2 and gastric cancer Cancer Fronteer 2004, 16, 29–34 (in Japanese).
  34. Smith GV, Feakins R, Farthing MJG, Ballinger A: Cyclooxygenase 2, p53, b−catenin, and APC protein expression in gastric adenomatous polyp. Am J Clin Pathol 2005, 123, 415–420.
  35. Ratnasinghe D, Tangrea JA, Roth MJ, Dawsey SM, Anver M, Kasprzak BA, Hu N, Wang QH, Taylor PR: Expression of cyclooxygenase−2 in human adenocarcinomas of the gastric cardia and corpus. Oncol Rep 1999, 6, 965–968.
  36. Yamagata R, Shimoyama T, Fukuda S, Yoshimura T, Tanaka M, Munakata A: Cyclooxygenase−2 expression is increased in early intestinal−type gastric cancer and gastric mucosa with intestinal metaplasia. Eur J Gastroenterol Hepatol 2002, 14, 359–363.
  37. Saukkonen K, Nieminen O, van Rees B, Vilkki S, Harkonen M, Juhola M, Mecklin JP, Sipponen P, Ristimaki A: Expression of cyclooxygenase−2 in dysplasia of the stomach and in intestinal−type gastric adenocarcinoma. Clin Cancer Res. 2001, 7, 1923–31.
  38. Joo YE, Oh WT, Rew JS, Park CS, Choi SK, Kim SJ: Cyclooxygenase−2 expression is associated with welldifferentiated and intestinal−type pathways in gastric carcinogenesis. Digestion 2002, 66, 222–229.
  39. Lim HY, Joo HJ, Choi JH, Yi JW, Yang MS, Cho DY, Kim HS, Nam DK, Lee KB, Kim HC: Increased expression of cyclooxygenase−2 protein in human gastric carcinoma. Clin Cancer Res 2000, 6, 519–525.
  40. Yamamoto H, Itoh F, Fukushima H, Hinoda Y, Imai K: Overexpression of cyclooxygenase−2 protein is less frequent in gastric cancers with microsatellite instability. Int J Cancer 1999, 84, 400–403.
  41. Rajnakova A, Moochhala S, Goh PM, Ngoi S: Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer. Cancer Lett 2001, 172, 177–185.
  42. Kawabe A, Shimada Y, Uchida S, Maeda M, Yamasaki S, Kato M, Hashimoto Y, Ohshio G, Matsumoto M, Imamura M: Expression of cyclooxygenase−2 in primary and remnant gastric carcinoma: comparing it with p53 accumulation, Helicobacter pylori infection, and vascular endothelial growth factor expression. J Surg Oncol 2002, 80, 79–88.
  43. Leung WK, To KF, Ng YP, Lee TL, Lau JY, Chan FK, Ng EK, Chung SC, Sung JJ: Association between cyclo−oxygenase−2 overexpression and missense p53 mutations in gastric cancer. Br J Cancer 2001, 84, 335–339.
  44. Baoping Y, Guoyong H, Jieping Y, Zongxue R, Hesheng L: Cyclooxygenase−2 inhibitor nimesulide suppresses telomerase activity by blocking Akt/PKB activation in gastric cancer cell line. Dig Dis Sci 2004, 49, 948–953.
  45. Fu YG, Sung JJ, Wu KC, Wu HP, Yu J, Chan M, Chan VY, Chan KK, Fan DM, Leung WK: Inhibition of gastric cancer−associated angiogenesis by antisense COX−2 transfectants. Cancer Lett 2005, 224, 243–252.
  46. Sawaoka H, Kawano S, Tsuji S, Tsujii M, Gunawan ES, Takei Y, Nagano K, Hori M: Cyclooxygenase−2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol. 1998, 274, G1061–G1067.
  47. Yashiro M, Nakazawa K, Tendo M, Kosaka K, Shinto O, Hirakawa K: Selective cyclooxygenase−2 inhibitor downregulates the paracrine epithelial−mesenchymal interactions of growth in scirrhous gastric carcinoma. Int J Cancer 2007, 120, 686–693.
  48. Hu PJ, Yu J, Zeng ZR, Leung WK, Lin HL, Tang BD, Bai AH, Sung JJ: Chemoprevention of gastric cancer by celecoxib in rats. Gut 2004, 53, 195–200.
  49. Kim TI, Lee YC, Lee KH, Han JH, Chon CY, Moon YM, Kang JK, Park IS: Effects of nonsteroidal antiinflammatory drugs on Helicobacter pylori−infected gastric mucosae of mice: apoptosis, cell proliferation, and inflammatory activity. Infect Immun 2001, 69, 5056–5063.
  50. Leung WK, Ng EK, Chan FK, Chan WY, Chan KF, Auyeung AC, Lam CC, Lau JY, Sung JJ: Effects of long−term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial. Clin Cancer Res 2006, 12, 4766–4772.
  51. Konturek PC, Konturek SJ, Bielanski W, Kania J, Zuchowicz M, Hartwich A, Rehfeld JF, Hahn EG: Influence of COX−2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis−related proteins in gastric cancer patients. Dig Dis Sci 2003, 48, 2005–2017.
  52. Bertagolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim KM, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj M, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006, 355, 873–884.
  53. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B: PreSAP Trial Investigators Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006, 355, 885–895.
  54. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, Bolognese JA, Oxenius B, Horgan K, Loftus S, Morton DG: APPROVe Trial Investigators. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006, 131, 1674–1682.
  55. Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES, Milne GL, Katkuri S, DuBois RN: 15−Hydroxyprostaglandin dehydrogenase is down−regulated in colorectal cancer. J Biol Chem 2005, 280, 3217–3223.
  56. Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, Lawrence E, Dannenberg AJ, Lovgren AK, Luo G, Pretlow TP, Newman RA, Willis J, Dawson D, Markowitz SD: 15−Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci USA 2006, 103, 12098–12102.